medigraphic.com

2014, Number 4

<< Back Next >>

Cir Cir 2014; 82 (4)

Polymorphism g.37190613 G›A of the ELMO1 gene in the Mexican population: potential marker for clinical-surgical pathology

Topete-González LR, Ramirez-Garcia SA, Charles-Niño C, Villa-Ruano N, Mosso-González C, Dávalos-Rodríguez NO

Language: Spanish
References: 25
Page: 402-411
PDF size: 481.49 Kb.


ABSTRACT

Background: ELMO1 is a gene located at locus 7p14.2-14.1 that codifies a regulatory protein involved in fibrogenesis, cell migration, phagocytosis and apoptosis. This gene presents a single nucleotide polymorphism, which appears to be linked with the development of diabetic nephropathy.
Objectives: Currently, there are no studies in regard to the presence of such polymorphism in the Mexican population. Therefore, the aim of this work was to estimate the frequency rate of alleles and genotypes of polymorphism rs1345365 from ELMO1 in Mexican mestizos who inhabit the west and the southeast regions of Mexico in order to generate reliable data for further association studies.
Methods: There were 322 individuals who were screened for the identification of polymorphism rs1345365 using genomic DNA from leucocytes as a template for PCR-PASA reactions. Amplicons were separated in 7% PAGE and visualized after staining with silver nitrate.
Results: The reference allele (A) was the most frequent in both western and southeastern populations of Mexico. In addition, a different genotype distribution was found with respect to other populations. The results of this study indicate that both populations are in Hardy-Weinberg equilibrium (p ‹0.05).
Conclusion: This study also reveals a low frequency rate of the ancestral genotype for the polymorphism rs1345365 in mestizos from the western and southeastern regions of Mexico.


REFERENCES

  1. Sentíes-Gómez MD, Gálvez-Gastélum FJ, Meza-García E, Armendáriz-Borunda J. Hepatic fibrosis: role of matrix metalloproteases and TGFbeta. Gac Med Mex 2005;141(4):315-322.

  2. Dolores-Velázquez R, Lever-Rosas CD, Barrera-Franco JL, Padilla-Rosciano A, Frias-Mendivil M, Domínguez-Parra L. Tumores primarios benignos de la pared torácica. Resultados del tratamiento quirúrgico. Cir Cir 2007;75:419-424.

  3. Álvarez-Rodríguez FJ, Baeza-Herrera C, García-Cabello LM, Godoy-Esquivel AH, Atzin-Fuentes JL. Miofibromatosis infantile. Relato de una enfermedad desesperante. Cir Cir 2006;74(4):269-272.

  4. Vidal-González P, Cervantes-Castro J, Rojas-Reyna GA, Ramírez-Cerda C, Kunz-Martínez W, Toiber-Levy M. Mesenteritis esclerosante: presentación de tres casos y revisión de la literatura. Cir Cir 2008;76(4):343-348.

  5. Ferbeyre-Binelfa L, Ramírez-Bollas J, Bautista-Piña V, Espejo-Fonseca R, Ruvalcaba-Limón E, Serratos-Garduño E. Fibromatosis of the breast. Report of two cases and review of the literature. Cir Cir 2009;77(4):313-318.

  6. Veras-Castillo ER, Cárdenas-Camaerna L, Lyra-Gonzalez I, Muñoz-Valle JF, Lucano-Landeros S, Guerrosantos J, et al. Controlled Clinical Trial With Pirfenidone in the Treatment of Breast Capsular Contracture: Association of TGF-β Polymorphisms. Ann Plast Surg 2013;70(1):16-22.

  7. Armendáriz-Borunda J, Rincón AR, Muñoz-Valle JF, Bueno- Topete M, Oregón-Romero E, Islas-Carbajal MC, et al. Fibrogenic polymorphisms (TGF-ß, PAI-1, AT) in Mexican Patients With Established Liver Fibrosis. Potential Correlation With Pirfenidone Treatment. J Investig Med 2008;56(7):944-953.

  8. Pérez-Garcia G, Ramirez-Garcia SA, Corona-Trigeros J, Raya A, Lara S, Órnelas-Arana ML. Fibrosis Quística. In: Lara-Vélez V, Chávez-López R, Flores-Villacencio ME, Ramos-Zepeda A, editors. De la genética a la medicina genómica. Guadalajara, México: Universidad de Guadalajara; 2012. p. 135-138.

  9. Leticia del Carmen Baena-Ocampo, Luis Miguel Linares- González, Norma Marín-Arriga. Hamartoma Fibroso de la infancia. Informe de un caso. Cir Ciruj 2009;77(6):487-491.

  10. del Carmen Baena-Ocampo L, Reyes-Sánchez A, Alpízar- Aguirre A, Rosales-Olivares LM. Tumor de vaina nerviosa periférica malign asociado a neurofibromatosis tipo 1. Informe de dos casos. Cir Cir 2009;77(5):391-395.

  11. Oliva-Sánchez PF, Siqueiros-García JM, Vázquez-González JR, Saruwatari-Zavala G, Carnevale A. La medicina genómica en las políticas de salud pública: una perspectiva de investigadores mexicanos del área biomédica. Salud Pública Méx 2013;55(1):16-25.

  12. Pezzolesi MG, Katavetin P, Kure M, Poznik GD, Skupien J, Mychaleckyj JC, et al. Confirmation of Genetic Associations at ELMO1 in the GoKinD Collection Supports Its Role as a Susceptibility Gene in Diabetics Nephropathy. Diabetes 2009;58(11):2698-2702.

  13. Shimazaki A, Tanaka Y, Shinosaki T, Ikeda M, Watada H, Hirose T, et al. ELMO1 increases expression of extracellular matrix proteins and inhibits cell adhesion to ECMs. Kidney Int 2006;70(10):1769-1776.

  14. Leak TS, Perlegas PS, Smith SG, Keene KL, Hicks PJ, Langefeld CD, et al. Variants in Intron 13 of the ELMO1 Gene are Associated with Diabetic Nephropathy in African Americans. Ann Hum Genet 2009;73(2):152-159.

  15. Shimazaki A, Kawamura Y, Kanazawa A, Sekine A, Saito S, Tsunoda T, et al. Genetic Variation in the Gene Encoding ELMO1 are Associated With Susceptibility to Diabetic Nephropathy. Diabetes 2005;54(4):1171-1178.

  16. Hanson RL, Millis MP, Young NJ, Kobes S, Nelson RG, Knowler WC, et al. ELMO1 variants and susceptibility to diabetic nephropathy in Americans Indians. Mol Genet Metab 2010;101(4):383-390.

  17. Divers J, Freedman BI. Susceptibility genes in common complex kidney disease. Curr Opin Nephrol Hypertens 2010;19(1):79-84.

  18. Kim S, Abboud HE, Pahl MV, Tayek J, Snyder S, Tamkin J, et al. Examination of Association with Candidate Genes for Diabetic Nephropathy in a Mexican American Population. Clin Am Soc Nephrol 2010;5(6):1072-1078.

  19. Jimenez-Sanchez G, Silva-Zolezzi I, Hidalgo A, March S. Genomic medicine in México: Initial steps and the road ahead. Genome Res 2008;18(8):1191-1198.

  20. Parra EJ, Cameron E, Simmonds L, Valladares A, McKeigue P, Shriver M, et al. Association of TCF7L2 polymorphisms with type 2 diabetes in Mexico City. Clin Genet 2007;71(4):359- 366.

  21. Salazar-Flores J, Dondiego-Aldape R, Rubi-Castellanos R, Anaya-Palafox M, Nuño-Arana I, Canseco-Ávila LM, et al. Population structure and paternal admixture landscape on present-day Mexican-Mestizos revealed by Y-STR haplotypes. Am J Hum Biol 2010;22(3):401- 409.

  22. Lisker R, Ramírez E, Peñaloza R, Salamanca F. Red Cell Acid Phosphatase Types and GC Polymorphisms in Mérida, Oaxaca, León, and Saltillo, Mexico. Hum Biol1994;66(6):1103-1109.

  23. Romero FM, Sánchez C, Mendoza JE, Bailón J, Ruiz FJ, Díaz VL. Historia breve. Oaxaca. 2ed. México: Fondo para la Cultura Económica, 2011. p. 7-44.

  24. Flores-Alfaro E, Burguete-Garcia AI, Salazar-Martínez E. Diseños de Investigación en epidemiología genética. Rev Panam Salud Pública 2012;31(1):88-94.

  25. Sánchez-Parada MG, Álvarez-Rodríguez BA, Gómez-Meda B, Troyo-Sanromán R, Sánchez-Orozco LV, Zamora-Perez AL, et al. Association of Genetic Polymorphisms With Histological Grading of Necroinflamation, Staging of Fibrosis, and Liver Function in Mexicans With Chronic Hepatitis C Virus Infection. J Investig Med 2013;61(7):1088-1096.




2020     |     www.medigraphic.com